Glycosylation of erythropoietin affects receptor binding kinetics: Role of electrostatic interactions

被引:90
作者
Darling, RJ [1 ]
Kuchibhotla, U [1 ]
Glaesner, W [1 ]
Micanovic, R [1 ]
Witcher, DR [1 ]
Beals, JM [1 ]
机构
[1] Eli Lilly & Co, Lilly Res Labs, BioRes Technol & Prot, Indianapolis, IN 46285 USA
关键词
D O I
10.1021/bi0265022
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Erythropoietin (EPO) is a cytokine produced by the kidney whose function is to stimulate red blood cell production in the bone marrow. Previously, it was shown that the affinity of EPO for its receptor, EPOR, is inversely related to the sialylation of EPO carbohydrate. To better understand the properties of EPO that modulate its receptor affinity, various glycoforms were analyzed using surface plasmon resonance. The system used has been well characterized and is based on previous reports employing an EPOR-Fc chimera captured on a Protein A surface. Using three variants of EPO containing different levels of sialylation, we determined that sialic acid decreased the association rate constant (k(on)) about 3-fold. Furthermore, glycosylated EPO had a 20-fold slower k(on) than nonglycosylated EPO, indicating that the core carbohydrate also negatively impacted k(on). The effect of electrostatic forces on EPO binding was studied by measuring binding kinetics in varying NaCl concentrations. Increasing NaCl concentration resulted in a slower k(on) while having little impact on k(off), suggesting that long-range electrostatic interactions are primarily important in determining the rate of association between EPO and EPOR. Furthermore, the glycosylation content (i.e., nonglycosylated vs glycosylated, sialylated vs desialylated) affected the overall sensitivities of k(on) to [NaCl], indicating that sialic acid and the glycan itself each impact the overall effect of these electrostatic forces.
引用
收藏
页码:14524 / 14531
页数:8
相关论文
共 41 条
[1]  
BEALS JM, 2000, Patent No. 0032772
[2]  
CEBON J, 1990, J BIOL CHEM, V265, P4483
[3]  
Chapel S, 2001, J PHARMACOL EXP THER, V298, P820
[4]   Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics [J].
Chapel, SH ;
Veng-Pedersen, P ;
Schmidt, RL ;
Widness, JA .
EXPERIMENTAL HEMATOLOGY, 2001, 29 (04) :425-431
[5]   Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain [J].
Constantinescu, SN ;
Keren, T ;
Socolovsky, M ;
Nam, HS ;
Henis, YI ;
Lodish, HF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (08) :4379-4384
[6]  
DUBE S, 1988, J BIOL CHEM, V263, P17516
[7]   Development and characterization of novel erythropoiesis stimulating protein (NESP) [J].
Egrie, JC ;
Browne, JK .
BRITISH JOURNAL OF CANCER, 2001, 84 (Suppl 1) :3-10
[8]   Experimental assignment of the structure of the transition state for the association of barnase and barstar [J].
Frisch, C ;
Fersht, AR ;
Schreiber, G .
JOURNAL OF MOLECULAR BIOLOGY, 2001, 308 (01) :69-77
[9]  
Glaspy J, 2001, BRIT J CANCER, V84, P1, DOI 10.1054/bjoc.2001.1745
[10]   Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report [J].
Heatherington, AC ;
Schuller, J ;
Mercer, AJ .
BRITISH JOURNAL OF CANCER, 2001, 84 (Suppl 1) :11-16